Integra Lifesciences (NASDAQ:IART) was downgraded by equities research analysts at Bank of America from a “buy” rating to a “neutral” rating in a note issued to investors on Tuesday, January 2nd, MarketBeat Ratings reports.
Several other equities research analysts have also issued reports on the company. Oppenheimer reissued a “buy” rating and set a $60.00 price objective on shares of Integra Lifesciences in a research note on Monday, September 18th. Barclays restated an “equal weight” rating and set a $53.00 price target (up previously from $47.00) on shares of Integra Lifesciences in a research report on Tuesday, September 12th. Zacks Investment Research downgraded Integra Lifesciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 25th. Jefferies Group reiterated a “buy” rating and issued a $58.00 price objective on shares of Integra Lifesciences in a report on Thursday, October 12th. Finally, Wells Fargo & Co downgraded Integra Lifesciences from an “outperform” rating to a “market perform” rating in a report on Sunday, October 29th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $52.70.
Shares of Integra Lifesciences (IART) traded up $1.30 on Tuesday, hitting $50.47. The company had a trading volume of 483,000 shares, compared to its average volume of 718,275. Integra Lifesciences has a one year low of $40.51 and a one year high of $56.42. The stock has a market capitalization of $3,980.00, a P/E ratio of 82.74, a price-to-earnings-growth ratio of 1.55 and a beta of 0.65. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26.
Integra Lifesciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, October 26th. The life sciences company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.47 by ($0.02). Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The firm had revenue of $278.83 million for the quarter, compared to the consensus estimate of $286.00 million. During the same period last year, the company posted $0.93 earnings per share. Integra Lifesciences’s revenue for the quarter was up 11.4% on a year-over-year basis. sell-side analysts anticipate that Integra Lifesciences will post 1.85 EPS for the current year.
In other news, VP Richard D. Gorelick sold 1,500 shares of the company’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $47.19, for a total value of $70,785.00. Following the completion of the sale, the vice president now directly owns 21,665 shares in the company, valued at approximately $1,022,371.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Barbara B. Hill bought 10,768 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was purchased at an average cost of $46.66 per share, with a total value of $502,434.88. Following the acquisition, the director now directly owns 55,540 shares in the company, valued at approximately $2,591,496.40. The disclosure for this purchase can be found here. 21.50% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Acrospire Investment Management LLC increased its position in shares of Integra Lifesciences by 280.0% during the second quarter. Acrospire Investment Management LLC now owns 1,900 shares of the life sciences company’s stock worth $104,000 after acquiring an additional 1,400 shares during the period. Riverhead Capital Management LLC increased its position in shares of Integra Lifesciences by 49.9% during the second quarter. Riverhead Capital Management LLC now owns 2,399 shares of the life sciences company’s stock worth $131,000 after acquiring an additional 799 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Integra Lifesciences by 8.6% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,752 shares of the life sciences company’s stock worth $150,000 after acquiring an additional 218 shares during the period. Whittier Trust Co. purchased a new position in shares of Integra Lifesciences during the third quarter worth approximately $169,000. Finally, San Francisco Sentry Investment Group CA purchased a new position in shares of Integra Lifesciences during the second quarter worth approximately $174,000. Hedge funds and other institutional investors own 87.58% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.